Cargando…

Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms

BACKGROUND: Circulating endothelial cells (CEC) may be a biomarker of vascular injury and pro-thrombotic tendency, while circulating endothelial progenitor cells (CEP) may be an indicator for angiogenesis and vascular remodelling. However, there is not a universally accepted standardized protocol to...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Cláudia, Fonseca, Ana Mafalda, Leander, Magdalena, Matos, Rui, Morais, Sara, Campos, Manuel, Lima, Margarida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855326/
https://www.ncbi.nlm.nih.gov/pubmed/24339944
http://dx.doi.org/10.1371/journal.pone.0081574
_version_ 1782294912605093888
author Torres, Cláudia
Fonseca, Ana Mafalda
Leander, Magdalena
Matos, Rui
Morais, Sara
Campos, Manuel
Lima, Margarida
author_facet Torres, Cláudia
Fonseca, Ana Mafalda
Leander, Magdalena
Matos, Rui
Morais, Sara
Campos, Manuel
Lima, Margarida
author_sort Torres, Cláudia
collection PubMed
description BACKGROUND: Circulating endothelial cells (CEC) may be a biomarker of vascular injury and pro-thrombotic tendency, while circulating endothelial progenitor cells (CEP) may be an indicator for angiogenesis and vascular remodelling. However, there is not a universally accepted standardized protocol to identify and quantify these cells and its clinical relevancy remains to be established. OBJECTIVES: To quantify CEC and CEP in patients with venous thromboembolism (VTE) and with myeloproliferative neoplasms (MPN), to characterize the CEC for the expression of activation (CD54, CD62E) and procoagulant (CD142) markers and to investigate whether they correlate with other clinical and laboratory data. PATIENTS AND METHODS: Sixteen patients with VTE, 17 patients with MPN and 20 healthy individuals were studied. The CEC and CEP were quantified and characterized in the blood using flow cytometry, and the demographic, clinical and laboratory data were obtained from hospital records. RESULTS: We found the CEC counts were higher in both patient groups as compared to controls, whereas increased numbers of CEP were found only in patients with MPN. In addition, all disease groups had higher numbers of CD62E+ CEC as compared to controls, whereas only patients with VTE had increased numbers of CD142+ and CD54+ CEC. Moreover, the numbers of total and CD62+ CEC correlated positively with the white blood cells (WBC) counts in both groups of patients, while the numbers of CEP correlated positively with the WBC counts only in patients with MPN. In addition, in patients with VTE a positive correlation was found between the numbers of CD54+ CEC and the antithrombin levels, as well as between the CD142+ CEC counts and the number of thrombotic events. CONCLUSIONS: Our study suggests that CEC counts may reveal endothelial injury in patients with VTE and MPN and that CEC may express different activation-related phenotypes depending on the disease status.
format Online
Article
Text
id pubmed-3855326
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38553262013-12-11 Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms Torres, Cláudia Fonseca, Ana Mafalda Leander, Magdalena Matos, Rui Morais, Sara Campos, Manuel Lima, Margarida PLoS One Research Article BACKGROUND: Circulating endothelial cells (CEC) may be a biomarker of vascular injury and pro-thrombotic tendency, while circulating endothelial progenitor cells (CEP) may be an indicator for angiogenesis and vascular remodelling. However, there is not a universally accepted standardized protocol to identify and quantify these cells and its clinical relevancy remains to be established. OBJECTIVES: To quantify CEC and CEP in patients with venous thromboembolism (VTE) and with myeloproliferative neoplasms (MPN), to characterize the CEC for the expression of activation (CD54, CD62E) and procoagulant (CD142) markers and to investigate whether they correlate with other clinical and laboratory data. PATIENTS AND METHODS: Sixteen patients with VTE, 17 patients with MPN and 20 healthy individuals were studied. The CEC and CEP were quantified and characterized in the blood using flow cytometry, and the demographic, clinical and laboratory data were obtained from hospital records. RESULTS: We found the CEC counts were higher in both patient groups as compared to controls, whereas increased numbers of CEP were found only in patients with MPN. In addition, all disease groups had higher numbers of CD62E+ CEC as compared to controls, whereas only patients with VTE had increased numbers of CD142+ and CD54+ CEC. Moreover, the numbers of total and CD62+ CEC correlated positively with the white blood cells (WBC) counts in both groups of patients, while the numbers of CEP correlated positively with the WBC counts only in patients with MPN. In addition, in patients with VTE a positive correlation was found between the numbers of CD54+ CEC and the antithrombin levels, as well as between the CD142+ CEC counts and the number of thrombotic events. CONCLUSIONS: Our study suggests that CEC counts may reveal endothelial injury in patients with VTE and MPN and that CEC may express different activation-related phenotypes depending on the disease status. Public Library of Science 2013-12-05 /pmc/articles/PMC3855326/ /pubmed/24339944 http://dx.doi.org/10.1371/journal.pone.0081574 Text en © 2013 Torres et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Torres, Cláudia
Fonseca, Ana Mafalda
Leander, Magdalena
Matos, Rui
Morais, Sara
Campos, Manuel
Lima, Margarida
Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms
title Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms
title_full Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms
title_fullStr Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms
title_full_unstemmed Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms
title_short Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms
title_sort circulating endothelial cells in patients with venous thromboembolism and myeloproliferative neoplasms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855326/
https://www.ncbi.nlm.nih.gov/pubmed/24339944
http://dx.doi.org/10.1371/journal.pone.0081574
work_keys_str_mv AT torresclaudia circulatingendothelialcellsinpatientswithvenousthromboembolismandmyeloproliferativeneoplasms
AT fonsecaanamafalda circulatingendothelialcellsinpatientswithvenousthromboembolismandmyeloproliferativeneoplasms
AT leandermagdalena circulatingendothelialcellsinpatientswithvenousthromboembolismandmyeloproliferativeneoplasms
AT matosrui circulatingendothelialcellsinpatientswithvenousthromboembolismandmyeloproliferativeneoplasms
AT moraissara circulatingendothelialcellsinpatientswithvenousthromboembolismandmyeloproliferativeneoplasms
AT camposmanuel circulatingendothelialcellsinpatientswithvenousthromboembolismandmyeloproliferativeneoplasms
AT limamargarida circulatingendothelialcellsinpatientswithvenousthromboembolismandmyeloproliferativeneoplasms